ReCode Therapeutics Initiates Phase 1 Trial of Inhaled mRNA Therapy RCT2100 for Cystic Fibrosis

ReCode Therapeutics, a pioneering genetic medicines company focused on tissue-specific delivery, has commenced the dosing of the initial cohort of healthy volunteer participants in a Phase 1 clinical study for RCT2100. This investigational therapy, delivered through inhalation, is designed to address cystic fibrosis (CF) patients with nonsense mutations, constituting approximately 10-13% of the CF population, who either do not respond to or experience adverse effects with approved CFTR modulators.

Dr. David Lockhart, Chief Scientific Officer and President of ReCode Therapeutics, emphasized the significance of this milestone for the CF community, highlighting RCT2100 as the second candidate developed using the company's innovative Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform, with the potential to provide therapeutic benefits to a broader spectrum of CF patients, including those with rare mutations.